L’actualité de Novigenix
Suivez toute l’actualité de Novigenix
Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for whole-blood RNA biomarkers, and mapping
Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society for Medical Oncology (ESMO) GI
Novigenix Appoints Dr. Pedro Romero as Director of Medical & Scientific Affairs
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune oncology expertise to the team.
Novigenix announces first closing of its $20M Series B financing round
Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s Liquid Immuno-Transcriptomic (LITOseek) platform provides
Novigenix remporte le prix Felix Burda 2021 en Médecine et Science
Catégorie « Innovation en immuno-transcriptomique pour la détection précoce du cancer colorectal » Le prix récompense l'excellence en matière d'innovation et l'impact dans la détection précoce du cancer LAUSANNE, SUISSE - 22 juillet 2021 - Novigenix SA, une biotech suisse à la pointe du développement et de la commercialisation de solutions en oncologie de précision basé sur l’immuno-transcriptomique,
Novigenix nomme Jan Groen au poste de CEO pour conduire la transition de la société vers une plateforme technologique de diagnostic du cancer et de médecine de précision
La plateforme ImmunoTranscriptomic combine l'identification des signatures d'ARNm de cellules immunitaires avec l'IA pour la détection précoce du cancer LAUSANNE, SUISSE - 7h00, CET, 13 mai 2019 - Novigenix SA, une société pionnière en ImmunoTranscriptomics qui développe et commercialise des produits pour la détection précoce du cancer et la médecine de précision a annoncé aujourd'hui la nomination du Dr